BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) today announced that it has reached an agreement with Sarissa Capital Management LP (“Sarissa Capital”), a beneficial owner of approximately 5% of the company’s outstanding ordinary shares

Lead Candidate VP-001 for Treatment of Retinitis Pigmentosa Type 11 Moves Closer to Clinical Development; Larger Animal Model Readouts on Track for 2021, with IND Submission Expected in mid 2022 First Preclinical Study in the CNS Shows Company’s PPMO Technology Can Be Successfully Applied Across High Value Target Tissues Beyond The Eye; Company Expects to Nominate CNS Candidate This Year

Castle Biosciences Supports American Academy of Dermatology’s “Skin Cancer, Take a Hike! ™ " Steps Challenge for Skin Cancer Awareness Month The month-long fundraising event invites the public to help log 9,500 miles in honor of the approximately 9,500 people diagnosed with skin cancer every day

Net sales of $106 million, up 1% compared to prior year, after a strong recovery in March U.S. Spinal Implants net sales grew 19% compared to prior year, as net sales increased for both Spine Fixation and Motion Preservation Performed the first cervical and lumbar procedures utilizing our new 3D-printed titanium interbody implants with Nanovate™ Technology .

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

Single-Use H-SteriScopes™ Added to Olympus Bronchoscopic Portfolio, Offering Flexibility and Choice to Physicians Performing Advanced Procedures

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility ”), which will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation Capital Inc.

Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System

- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95 - Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis; Adjusted Net Revenues Were $12.935 Billion

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, presented posters on two data sets from the Company’s Phase 3 VANISH Program demonstrating the therapeutic potential of ibrexafungerp (Brexafemme) as a treatment for vulvovaginal candidiasis (VVC